Peninsula cancer test developer to pay $70M upfront for Israeli company

Although financial terms of the South San Francisco company’s deal with C2i Genomics are relatively small in the realm of life sciences transaction, the acquisition potentially is big for Veracyte.
Click here to view original post

ADVERTISEMENT — Advertise With Biotech Networks